Login to Your Account

Boehringer seals $201M Dicerna deal targeting NASH and other liver diseases

By Michael Fitzhugh
Staff Writer

Thursday, November 2, 2017

Boehringer Ingelheim GmbH is enlisting early stage RNAi specialist Dicerna Pharmaceuticals Inc. to discover and develop new therapies for chronic liver diseases, starting with nonalcoholic steatohepatitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription